Annual Meeting GU 2016 Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer at ASCO GU 2016